Health on MSN14 小时
What Is the Prognosis of Multiple Myeloma?
Medically reviewed by Doru Paul, MD Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white ...
Targeted Oncology16 天
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Military.com19 天
VA Set to Add Leukemia, Multiple Myeloma to List of Conditions Linked to Burn Pits
The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as linked to military service in the Persian Gulf, Afghanistan and ...
The American Journal of Managed Care25 天
Eque-Cel CAR T Shows Strong Results for Multiple Myeloma
Equecabtagene autoleucel showed high efficacy in relapsed/refractory multiple myeloma, with a 96% overall response rate and 42.6% complete response rate at three months. Minimal residual disease ...
FierceBiotech26 天
ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead Sciences' Kite Pharma to treat relapsed or refractory multiple myeloma (RRMM). After seeing the data ...
STAT27 天
Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit
Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...
BioPharma Dive27 天
Cancer cell therapy from Arcellx, Gilead shows promise in early data
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare. Carvykti ...